CN1774258A - 肺病治疗 - Google Patents
肺病治疗 Download PDFInfo
- Publication number
- CN1774258A CN1774258A CNA03807463XA CN03807463A CN1774258A CN 1774258 A CN1774258 A CN 1774258A CN A03807463X A CNA03807463X A CN A03807463XA CN 03807463 A CN03807463 A CN 03807463A CN 1774258 A CN1774258 A CN 1774258A
- Authority
- CN
- China
- Prior art keywords
- atiii
- antithrombin iii
- lung
- injury
- treatment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 208000019693 Lung disease Diseases 0.000 title abstract description 4
- 102000004411 Antithrombin III Human genes 0.000 claims abstract description 77
- 108090000935 Antithrombin III Proteins 0.000 claims abstract description 77
- 229960005348 antithrombin iii Drugs 0.000 claims abstract description 77
- 238000000034 method Methods 0.000 claims abstract description 22
- 230000006378 damage Effects 0.000 claims abstract description 18
- 206010035664 Pneumonia Diseases 0.000 claims abstract description 13
- 210000004072 lung Anatomy 0.000 claims description 13
- 238000002360 preparation method Methods 0.000 claims description 11
- 208000027418 Wounds and injury Diseases 0.000 claims description 9
- 208000014674 injury Diseases 0.000 claims description 9
- 230000009261 transgenic effect Effects 0.000 claims description 8
- 206010069351 acute lung injury Diseases 0.000 claims description 7
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 claims description 6
- 208000013616 Respiratory Distress Syndrome Diseases 0.000 claims description 6
- 208000011341 adult acute respiratory distress syndrome Diseases 0.000 claims description 6
- 201000000028 adult respiratory distress syndrome Diseases 0.000 claims description 6
- 230000037396 body weight Effects 0.000 claims description 6
- 210000002381 plasma Anatomy 0.000 claims description 5
- 230000008521 reorganization Effects 0.000 claims description 5
- 230000003612 virological effect Effects 0.000 claims description 5
- 241000589516 Pseudomonas Species 0.000 claims description 4
- 239000003795 chemical substances by application Substances 0.000 claims description 4
- 238000002604 ultrasonography Methods 0.000 claims description 4
- 239000010425 asbestos Substances 0.000 claims description 3
- 229910052895 riebeckite Inorganic materials 0.000 claims description 3
- 208000004852 Lung Injury Diseases 0.000 abstract description 3
- 206010069363 Traumatic lung injury Diseases 0.000 abstract description 3
- 239000000443 aerosol Substances 0.000 description 20
- 241001494479 Pecora Species 0.000 description 12
- 206010040047 Sepsis Diseases 0.000 description 10
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 8
- 239000003814 drug Substances 0.000 description 8
- 238000012360 testing method Methods 0.000 description 8
- 150000001875 compounds Chemical class 0.000 description 7
- 239000007789 gas Substances 0.000 description 7
- 229940079593 drug Drugs 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 238000001990 intravenous administration Methods 0.000 description 6
- 241001465754 Metazoa Species 0.000 description 5
- 239000007788 liquid Substances 0.000 description 5
- 239000000203 mixture Substances 0.000 description 5
- 230000002685 pulmonary effect Effects 0.000 description 5
- 206010061218 Inflammation Diseases 0.000 description 4
- 230000001154 acute effect Effects 0.000 description 4
- 230000004054 inflammatory process Effects 0.000 description 4
- 208000024891 symptom Diseases 0.000 description 4
- 201000008827 tuberculosis Diseases 0.000 description 4
- 238000000889 atomisation Methods 0.000 description 3
- 238000004113 cell culture Methods 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 239000003380 propellant Substances 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- 241000283690 Bos taurus Species 0.000 description 2
- 241000283707 Capra Species 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 208000029523 Interstitial Lung disease Diseases 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- 206010035610 Pleural Neoplasms Diseases 0.000 description 2
- 241000589517 Pseudomonas aeruginosa Species 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 230000004872 arterial blood pressure Effects 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 230000008021 deposition Effects 0.000 description 2
- 230000003203 everyday effect Effects 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 239000002502 liposome Substances 0.000 description 2
- 231100000515 lung injury Toxicity 0.000 description 2
- 208000020816 lung neoplasm Diseases 0.000 description 2
- 235000013336 milk Nutrition 0.000 description 2
- 239000008267 milk Substances 0.000 description 2
- 210000004080 milk Anatomy 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 230000036470 plasma concentration Effects 0.000 description 2
- 208000008423 pleurisy Diseases 0.000 description 2
- 238000005507 spraying Methods 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 231100001274 therapeutic index Toxicity 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 229920000742 Cotton Polymers 0.000 description 1
- 102000009123 Fibrin Human genes 0.000 description 1
- 108010073385 Fibrin Proteins 0.000 description 1
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 1
- 102000004895 Lipoproteins Human genes 0.000 description 1
- 108090001030 Lipoproteins Proteins 0.000 description 1
- 101150034459 Parpbp gene Proteins 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 235000020244 animal milk Nutrition 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000001746 atrial effect Effects 0.000 description 1
- 230000023555 blood coagulation Effects 0.000 description 1
- 230000036760 body temperature Effects 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 229950003499 fibrin Drugs 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 231100000636 lethal dose Toxicity 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 210000001147 pulmonary artery Anatomy 0.000 description 1
- 239000010453 quartz Substances 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 238000009938 salting Methods 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N silicon dioxide Inorganic materials O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 238000011125 single therapy Methods 0.000 description 1
- 239000000779 smoke Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 230000002861 ventricular Effects 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/55—Protease inhibitors
- A61K38/57—Protease inhibitors from animals; from humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Pulmonology (AREA)
- Dispersion Chemistry (AREA)
- Otolaryngology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Description
治疗 | 盐溶液 | 抗凝血酶III |
PaO2/FiO2 | 94±22 | 206±41* |
分流系数(%) | 45±5 | 23±4* |
MAP(mmHg) | 71.3±9.0 | 84.6±12.0 |
肺湿/干比 | 6.4±0. | 5.4±0.1* |
Claims (13)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US36899702P | 2002-04-01 | 2002-04-01 | |
US60/368,997 | 2002-04-01 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1774258A true CN1774258A (zh) | 2006-05-17 |
CN100384469C CN100384469C (zh) | 2008-04-30 |
Family
ID=29420316
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CNB03807463XA Expired - Fee Related CN100384469C (zh) | 2002-04-01 | 2003-03-25 | 肺病治疗药物 |
Country Status (10)
Country | Link |
---|---|
US (1) | US20090221475A9 (zh) |
EP (1) | EP1494696A4 (zh) |
JP (2) | JP2005527570A (zh) |
KR (2) | KR20040105838A (zh) |
CN (1) | CN100384469C (zh) |
AU (3) | AU2003233428B2 (zh) |
CA (1) | CA2480790A1 (zh) |
IL (2) | IL164078A0 (zh) |
NZ (1) | NZ535487A (zh) |
WO (1) | WO2003084476A2 (zh) |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20050169908A1 (en) * | 2004-01-23 | 2005-08-04 | Kazunori Murakami | Use of aerosolized antithrombin to treat acute lung injury |
US20050192226A1 (en) * | 2004-02-20 | 2005-09-01 | Perenlei Enkhbaatar | Method of preventing fibrin clots in pulmonary tissue through the use of aerosolized anticoagulants |
US20050245444A1 (en) * | 2004-04-30 | 2005-11-03 | Yann Echelard | Method of using recombinant human antithrombin for neurocognitive disorders |
US20060121004A1 (en) * | 2004-12-07 | 2006-06-08 | Yann Echelard | Methods of reducing the incidence of rejection in tissue transplantation through the use of recombinant human antithrombin |
US8753882B2 (en) | 2010-10-12 | 2014-06-17 | Vetgel Technologies | Methods and compositions for treating respiratory conditions using platelet enriched plasma |
CA2823005C (en) | 2010-12-30 | 2019-07-09 | Laboratoire Francais Du Fractionnement Et Des Biotechnologies | Glycols as pathogen inactivating agents |
TW201446962A (zh) | 2013-02-13 | 2014-12-16 | Lab Francais Du Fractionnement | 具有修飾的糖化作用之蛋白質及其製造方法 |
JP2016508515A (ja) | 2013-02-13 | 2016-03-22 | ラボラトワール フランセ デュ フラクショヌマン エ デ ビオテクノロジーLaboratoire Francais du Fractionnement et des Biotechnologies | 高ガラクトシル化抗TNF−α抗体およびその使用 |
KR20160029840A (ko) | 2013-07-05 | 2016-03-15 | 라보라토이레 프란카이즈 듀 프락티온네먼트 에트 데스 바이오테크놀로지스 | 친화성 크로마토그래피 매트릭스 |
EP3154694A1 (en) | 2014-06-13 | 2017-04-19 | Children's Medical Center Corporation | Products and methods to isolate mitochondria |
EP3955902B1 (en) * | 2019-04-15 | 2024-07-17 | Children's Medical Center Corporation | Aerosolized compositions comprising mitochondria and methods of use thereof |
Family Cites Families (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH08782B2 (ja) * | 1986-11-22 | 1996-01-10 | 株式会社ミドリ十字 | 抗炎症剤 |
DE4117078A1 (de) * | 1991-05-25 | 1992-11-26 | Boehringer Ingelheim Kg | Verfahren zur herstellung therapeutisch anwendbarer aerosole |
JPH06256213A (ja) * | 1993-03-03 | 1994-09-13 | Green Cross Corp:The | ヒト由来アンチトロンビン−iiiの医薬用途 |
US6127347A (en) * | 1994-01-12 | 2000-10-03 | Univ Michigan | Non-anticoagulant chemically modified heparinoids for treating hypovolemic shock and related shock syndromes |
US6355626B1 (en) * | 1994-05-13 | 2002-03-12 | The Trustees Of The University Of Pennsylvania | Antithrombin agents in treatment of asthma |
US5843705A (en) * | 1995-02-21 | 1998-12-01 | Genzyme Transgenic Corporation | Transgenically produced antithrombin III |
US6562781B1 (en) * | 1995-11-30 | 2003-05-13 | Hamilton Civic Hospitals Research Development Inc. | Glycosaminoglycan-antithrombin III/heparin cofactor II conjugates |
US7045585B2 (en) * | 1995-11-30 | 2006-05-16 | Hamilton Civic Hospital Research Development Inc. | Methods of coating a device using anti-thrombin heparin |
JPH09176040A (ja) * | 1995-12-27 | 1997-07-08 | Green Cross Corp:The | ヘパリンコファクターiiの医薬用途 |
US6063593A (en) * | 1996-11-12 | 2000-05-16 | University Of Southern California University Park Campus | TGFβ1 responsive bone marrow derived cells to express a recombinant protein |
US6124257A (en) * | 1997-08-28 | 2000-09-26 | Lezdey; John | Method of treatment |
CA2347248C (en) * | 1998-10-20 | 2011-09-20 | Children's Hospital Medical Center | Surfactant protein d for the prevention and diagnosis of pulmonary emphysema |
US6838428B2 (en) * | 1998-10-20 | 2005-01-04 | Children's Hospital Medical Center | Surfactant protein D for the prevention and diagnosis of pulmonary emphysema |
DE10045047A1 (de) * | 2000-09-12 | 2002-03-21 | Beate Kehrel | Arzneimittel enthaltend aktiviertes Antithrombin III |
AU2002224408B2 (en) * | 2000-10-18 | 2007-08-23 | Massachusetts Institute Of Technology | Methods and products related to pulmonary delivery of polysaccharides |
DE10132307A1 (de) * | 2001-07-06 | 2003-01-30 | Aventis Behring Gmbh | Arzneizubereitung zur Inhalation von Antithrombin bei entzündlichen Lungenerkrankungen und ARDS |
US20050169908A1 (en) * | 2004-01-23 | 2005-08-04 | Kazunori Murakami | Use of aerosolized antithrombin to treat acute lung injury |
US20050192226A1 (en) * | 2004-02-20 | 2005-09-01 | Perenlei Enkhbaatar | Method of preventing fibrin clots in pulmonary tissue through the use of aerosolized anticoagulants |
-
2003
- 2003-03-25 KR KR10-2004-7015636A patent/KR20040105838A/ko not_active Application Discontinuation
- 2003-03-25 WO PCT/US2003/009053 patent/WO2003084476A2/en active Application Filing
- 2003-03-25 AU AU2003233428A patent/AU2003233428B2/en not_active Revoked
- 2003-03-25 US US10/396,855 patent/US20090221475A9/en not_active Abandoned
- 2003-03-25 CN CNB03807463XA patent/CN100384469C/zh not_active Expired - Fee Related
- 2003-03-25 IL IL16407803A patent/IL164078A0/xx active IP Right Grant
- 2003-03-25 CA CA002480790A patent/CA2480790A1/en not_active Abandoned
- 2003-03-25 EP EP03728277A patent/EP1494696A4/en not_active Withdrawn
- 2003-03-25 KR KR1020107022448A patent/KR20100117148A/ko active Application Filing
- 2003-03-25 JP JP2003581716A patent/JP2005527570A/ja active Pending
- 2003-03-25 NZ NZ535487A patent/NZ535487A/en not_active IP Right Cessation
-
2004
- 2004-09-14 IL IL164078A patent/IL164078A/en not_active IP Right Cessation
-
2008
- 2008-10-31 AU AU2008243077A patent/AU2008243077A1/en not_active Withdrawn
-
2011
- 2011-08-12 JP JP2011176604A patent/JP2011225625A/ja not_active Withdrawn
- 2011-10-10 AU AU2011236070A patent/AU2011236070A1/en not_active Ceased
Also Published As
Publication number | Publication date |
---|---|
JP2005527570A (ja) | 2005-09-15 |
KR20100117148A (ko) | 2010-11-02 |
AU2003233428B2 (en) | 2008-07-31 |
AU2003233428A1 (en) | 2003-10-20 |
AU2008243077A1 (en) | 2008-11-27 |
US20040192595A1 (en) | 2004-09-30 |
CN100384469C (zh) | 2008-04-30 |
WO2003084476A3 (en) | 2004-04-22 |
EP1494696A4 (en) | 2006-01-25 |
KR20040105838A (ko) | 2004-12-16 |
EP1494696A2 (en) | 2005-01-12 |
US20090221475A9 (en) | 2009-09-03 |
CA2480790A1 (en) | 2003-10-16 |
NZ535487A (en) | 2008-12-24 |
IL164078A (en) | 2011-02-28 |
JP2011225625A (ja) | 2011-11-10 |
IL164078A0 (en) | 2005-12-18 |
AU2011236070A1 (en) | 2011-11-03 |
WO2003084476A2 (en) | 2003-10-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2011236070A1 (en) | Treatment of lung disorder | |
TWI417108B (zh) | 於肺內區中以半氟化烷類作為活性物質載體的吸入式及滴入式使用 | |
JPH03501852A (ja) | エアゾール化したポリエンを用いる肺の真菌感染の予防及び治療方法 | |
JPH0669957B2 (ja) | グルタチオンのエーロゾル製剤 | |
JP2774379B2 (ja) | 医薬エアロゾール組成物ならびにそれらのウイルス疾患の治療および予防用途 | |
JP5970465B2 (ja) | ペプチドおよびウイルス・ノイラミニダーゼ阻害剤を含んでなる組成物 | |
KR20140108516A (ko) | 폐 악화의 발현 또는 진행을 지연시키기 위한 알파1-프로테이나제 억제제 | |
US20200268656A1 (en) | Nebulized Ethanol for Internal Disinfecting and Improvement | |
RU2728821C1 (ru) | Способ лечения острого респираторного дистресс-синдрома даларгином и легочным сурфактантом | |
RU2728939C1 (ru) | Применение даларгина для производства средств лечения коронавирусной инфекции covid-19 | |
Brown et al. | Pathophysiological responses following phosgene exposure in the anaesthetized pig | |
Garcia-Contreras et al. | Aerosol treatment of cystic fibrosis | |
CN100394981C (zh) | 一种人粒细胞巨噬细胞集落刺激因子喷雾剂及其制备方法 | |
KR101924162B1 (ko) | 기도의 염증 및 이상성 점액섬모 전달의 치료법으로서의 에어로졸화 댑손 | |
KR20100093037A (ko) | 폐질환의 건강 관련 삶의 질 부족을 치료하기 위한 흡입용 아즈트레오남 라이신 | |
US20130123364A1 (en) | N6-(1-iminoethyl)-l-lysine for regeneration of alveoli in lungs | |
Cipolla et al. | Delivery of biologics to the lung | |
Challoner | Aerosol delivery of antibiotics | |
EP4255390A1 (en) | Compositions, devices, and methods for treating respiratory disorders | |
WO2023044487A1 (en) | Treatment of lung disease or injury using engineered antimicrobial peptides | |
CN115461356A (zh) | 用于预防或治疗covid-19的肽 | |
WO2024054226A1 (en) | Gallium nitrate and dimethyl sulfoxide composition for respiratory treatment | |
RU2262343C2 (ru) | Способ лечения гипоксии | |
Dal Negro et al. | Use of aerosols in bronchiectasis patients | |
JPWO2006078066A1 (ja) | 経気道呼吸器感染症治療剤 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 1087930 Country of ref document: HK |
|
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
ASS | Succession or assignment of patent right |
Owner name: UNIV. TEXAS Free format text: FORMER OWNER: GTC BIOTHERAPEUTIC CORP. Effective date: 20110422 |
|
C41 | Transfer of patent application or patent right or utility model | ||
COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: MASSACHUSETTS, THE USA TO: TEXAS, THE USA |
|
TR01 | Transfer of patent right |
Effective date of registration: 20110422 Address after: Texas in the United States Patentee after: Univ. Texas Address before: Massachusetts, USA Patentee before: GTC Biotherapeutic Corp. |
|
REG | Reference to a national code |
Ref country code: HK Ref legal event code: WD Ref document number: 1087930 Country of ref document: HK |
|
C17 | Cessation of patent right | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20080430 Termination date: 20120325 |